ONC 92592
Alternative Names: ONC-92592Latest Information Update: 28 Aug 2024
At a glance
- Originator XBiotech
- Class Anti-inflammatories; Antineoplastics; Monoclonal antibodies
- Mechanism of Action Interleukin 1 alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Aug 2024 No recent reports of development identified for preclinical development in Cancer in USA
- 22 Jul 2020 XBiotech plans a clinical trial for Cancer in USA in early 2021 (July 2020, XBiotech pipeline)
- 22 Jul 2020 ONC 92592 is available for licensing as of 22 Jul 2020. http://www.xbiotech.com/